Advertisement
Advertisement

ANIK

ANIK logo

Anika Therapeutics Inc

14.77
USD
Sponsored
-0.37
-2.44%
May 08, 15:59 UTC -4
Closed
exchange

After-Market

14.77

0.00
0.00%

ANIK Earnings Reports

Positive Surprise Ratio

ANIK beat 25 of 42 last estimates.

60%

Next Report

Date of Next Report
Jul 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$29.80M
/
-$0.08
Implied change from Q1 26 (Revenue/ EPS)
+0.63%
/
-129.63%
Implied change from Q2 25 (Revenue/ EPS)
+5.60%
/
-71.43%

Anika Therapeutics Inc earnings per share and revenue

On Apr 29, 2026, ANIK reported earnings of 0.27 USD per share (EPS) for Q1 26, beating the estimate of -0.16 USD, resulting in a 265.44% surprise. Revenue reached 29.61 million, compared to an expected 28.70 million, with a 3.16% difference. The market reacted with a -18.81% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.08 USD, with revenue projected to reach 29.80 million USD, implying an decrease of -129.63% EPS, and increase of 0.63% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
ANI Pharmaceuticals, Inc.
Report Date
May 08, 2026 For Q1 26
Estimate
$1.33
Actual
$2.04
Surprise
+54.04%
logo
Iovance Biotherapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.19
Surprise
-24.35%
logo
Corvus Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.15
Surprise
-2.95%
logo
Tectonic Therapeutic, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.20
Actual
-$1.34
Surprise
-11.07%
logo
Ginkgo Bioworks Holdings, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.09
Actual
-$1.28
Surprise
-17.35%
logo
ALX Oncology Holdings Inc. Common Stock
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.17
Surprise
+24.24%
logo
Codexis, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.10
Surprise
+28.26%
logo
Entera Bio Ltd. Ordinary Shares
Report Date
May 08, 2026 For Q1 26
Estimate
-$0.15
Actual
-$0.07
Surprise
+54.25%
logo
PTC Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.47
Actual
-$0.03
Surprise
+93.75%
logo
Scholar Rock Holding Corporation Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.81
Actual
-$0.83
Surprise
-1.62%
FAQ
For Q1 2026, Anika Therapeutics Inc reported EPS of $0.27, beating estimates by 265.44%, and revenue of $29.61M, 3.16% above expectations.
The stock price moved down -18.81%, changed from $15.26 before the earnings release to $12.39 the day after.
The next earning report is scheduled for Jul 28, 2026.
Based on 4 analysts, Anika Therapeutics Inc is expected to report EPS of -$0.08 and revenue of $29.80M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement